Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for phakomatosis cesiomarmorata has been reported in the published literature.
No clinical trials have been registered for phakomatosis cesiomarmorata.
114 publications have been identified in PubMed for phakomatosis cesiomarmorata. Research spans Review / Meta-Analysis (46%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 53 | 46% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
26 |
23% |
Disease patterns and progression | 16 | 14% |
Clinical study results | 7 | 6% |
New treatment approaches | 5 | 4% |
Patient case studies | 4 | 4% |
Testing and diagnosis research | 2 | 2% |
Other research | 1 | 1% |
Prasanna S (2026). [PMID: 41717942](https://pubmed.ncbi.nlm.nih.gov/41717942/). *Indian Dermatol Online J*. [Review / Meta-Analysis]
Nair HB (2026). [PMID: 41496346](https://pubmed.ncbi.nlm.nih.gov/41496346/). *Biomed Pharmacother*. [Review / Meta-Analysis]
Williams KB (2026). [PMID: 41036607](https://pubmed.ncbi.nlm.nih.gov/41036607/). *Mol Cancer Ther*. [Epidemiology / Natural History]
Ellenbogen Y (2026). [PMID: 41504793](https://pubmed.ncbi.nlm.nih.gov/41504793/). *J Neurooncol*. [Review / Meta-Analysis]
Vernimmen V (2026). [PMID: 41289058](https://pubmed.ncbi.nlm.nih.gov/41289058/). *Hum Reprod*. [Epidemiology / Natural History]
Agosti E (2026). [PMID: 41478004](https://pubmed.ncbi.nlm.nih.gov/41478004/). *Cancer Treat Rev*. [Review / Meta-Analysis]
Porche K (2026). [PMID: 41237393](https://pubmed.ncbi.nlm.nih.gov/41237393/). *J Neurosurg*. [Review / Meta-Analysis]
Scheper M (2026). [PMID: 41352576](https://pubmed.ncbi.nlm.nih.gov/41352576/). *Prog Neurobiol*. [Basic Science / Preclinical]
Winden K (2026). [PMID: 41820375](https://pubmed.ncbi.nlm.nih.gov/41820375/). *Nat Rev Dis Primers*. [Review / Meta-Analysis]
Gai Z (2026). [PMID: 41519401](https://pubmed.ncbi.nlm.nih.gov/41519401/). *Biochem Pharmacol*. [Review / Meta-Analysis]